4-(quinolin-4-ylmethoxy)aniline | 863498-58-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(quinolin-4-ylmethoxy)aniline
• CAS: 863498-58-2
• 化学式: C₁₆H₁₄N₂O
• 分子量: 250.3
• InChiKey: RCBPPMDINMTKRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(quinolin-4-ylmethoxy)aniline 在 乙醇 、 盐酸羟胺 、 水 、 铁粉 、 三乙胺 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 96.5h， 生成 3-amino-3-imino-N-[4-(quinolin-4-ylmethoxy)phenyl]propanamide hydrochloride
  参考文献：
  名称：

  WO2008/42867

  摘要：

  公开号：
• 作为产物：
  描述：

  4-喹啉甲醇 在 氢氧化钾 、 sodium hydroxide 、 乙醇 、 水 、 铁粉 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.1h， 生成 4-(quinolin-4-ylmethoxy)aniline
  参考文献：
  名称：

  WO2008/42867

  摘要：

  公开号：

文献信息

• Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents
  申请人：Jirgensons Aigars

  公开号：US20100311741A1

  公开（公告）日：2010-12-09

  This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-α Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-α, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in the inhibition of TACE, and in the treatment of conditions that are ameliorated by the inhibition of TACE.

  本发明涉及治疗化合物领域，更具体地涉及某些双环磺酸（BCSA）化合物，其作为肿瘤坏死因子-α转化酶（TACE）的抑制剂。这些化合物对于治疗由TNF-α介导的疾病非常有用，例如类风湿性关节炎；炎症；银屑病；脓毒症休克；移植排斥；消瘦症；厌食症；充血性心力衰竭；缺血再灌注损伤后；中枢神经系统炎症性疾病；炎症性肠病；胰岛素抵抗；HIV感染；癌症；慢性阻塞性肺疾病（COPD）和哮喘。本发明还涉及包括这些化合物的制药组合物，以及这些化合物和组合物的使用，无论是体外还是体内，用于抑制TACE并治疗通过抑制TACE得到改善的疾病。
• Rational design, synthesis and structure–activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 2: lead optimization
  作者：Chu-Biao Xue、Xiaohua He、John Roderick、Ronald L Corbett、James J.-W Duan、Rui-Qin Liu、Maryanne B Covington、Mingxin Qian、Maria D Ribadeneira、Krishna Vaddi、David D Christ、Robert C Newton、James M Trzaskos、Ronald L Magolda、Ruth R Wexler、Carl P Decicco

  DOI：10.1016/j.bmcl.2003.09.057

  日期：2003.12

  Modifications of the lead TACE inhibitor 1 (N-hydroxy-trans-2-[4-(4-quinolinyloxymethyl)anilinyl]carbonyl}-1-cyclo-hexanecarboxamide) at the cyclohexyl ring and the quinoline moiety led to the identification of a series of piperidine containing TACE inhibitors with potent activity in the inhibition of TNF-alpha release in the whole blood assay (WBA). The most potent analogue IM491 [N-hydroxy-(5S,6S)-1-methyl-6-[4-(2-methyl-4-quinolinylmethoxy)anilinyl]carbonyl}-5-piperidinecarboxamide] exhibited an IC50 value of 20 nM in WBA with excellent selectivity over MMP-1, -2 and -9 and is orally bioavailable with an F value of 43% in beagle dogs. (C) 2003 Elsevier Ltd. All rights reserved.
• [EN] MODULATORS OF MULTIPLE KINASES<br/>[FR] MODULATEURS DE KINASES MULTIPLES
  申请人：EMILIEM INC

  公开号：WO2008042867A2

  公开（公告）日：2008-04-10

  [EN] Compound structures are provided which should modulate various selected kinases thereby regulating the corresponding kinase signal pathways. These pathways have been shown to regulate biological functions. The compounds, and similar variants, will be useful in therapeutic or diagnostic methods related to said kinases. In particular, improved effects on functional pathways mediated by kinases can be achieved by modulating selected combinations of kinases.
  [FR] L'invention concerne des structures de composés destinées à moduler diverses kinases sélectionnées par la régulation des voies de signalisation de kinases correspondantes. Ces voies sont aptes à réguler des fonctions biologiques. Ces composés, et des variants similaires, peuvent être utiles dans des méthodes thérapeutiques ou diagnostiques liées à ces kinases. La présente invention permet en particulier d'améliorer les effets sur les voies fonctionnelles à médiation de kinases, par la modulation de combinaisons choisies de kinases.
• [EN] BICYCLOSULFONYL ACID (BCSA) COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS DE L'ACIDE BICYCLOSULFONYLIQUE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：INHIBOX LTD

  公开号：WO2008142376A1

  公开（公告）日：2008-11-27

  [EN] This invention pertains generally to the field of therapeutic compounds, and more particularly, to certain bicyclosulfonyl acid (BCSA) compounds which act as inhibitors of Tumour Necrosis Factor-a Converting Enzyme (TACE). The compounds are useful in the treatment of conditions mediated by TNF-a, such as rheumatoid arthritis; inflammation; psoriasis; septic shock; graft rejection; cachexia; anorexia; congestive heart failure; post ischaemic reperfusion injury; inflammatory disease of the central nervous system; inflammatory bowel disease; insulin resistance; HIV infection; cancer; chronic obstructive pulmonary disease (COPD); and asthma. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in
  [FR] Cette invention appartient d'une manière générale au domaine des composés thérapeutiques et plus particulièrement, à certain composés de l'acide bicyclosulfonylique (BCSA) qui agissent comme inhibiteurs de l'enzyme de conversion du facteur a de nécrose tumorale (TACE). Ces composés s'avèrent utiles dans le traitement de états médiés par le TNF-a, tels que la polyarthrite chronique évolutive; l'inflammation; le psoriasis; le choc septique; le rejet de greffe; la cachexie; l'anorexie; l'insuffisance cardiaque congestive; les maladies inflammatoires du SNC; l'affection abdominale inflammatoire; la résistance à l'insuline; l'infection par le VIH; le cancer; la bronchopneumopathie chronique obstructive et l'asthme. L'invention porte également sur des compositions pharmaceutiques comprenant de tels composés et sur l'utilisation de tels composés et compositions, tant in vitro qu'in vivo, pour l'inhibition du TACE et pour le traitement d'états améliorées par l'inhibition du TACE.
• WO2008/42867
  申请人：——

  公开号：——

  公开（公告）日：——